Sofwave Medical reported Q2 and first-half 2026 financial results and business highlights, with revenue acceleration driven by adoption of its ultrasonic RF microneedling platform. The company continues to gain traction in the competitive RF space.
Devices & Tech
Sofwave Q2 Revenue Accelerates on Ultrasonic Demand
Ultrasonic RF microneedling platform shows strong uptake; company reports Q2 and H1 results.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
Ultrasonic RF microneedling platform driving revenue acceleration in competitive device market.
Sofwave's ultrasonic RF approach differentiates on depth control and thermal profile compared to conventional RF microneedling, which can appeal to practices seeking a clinical edge. The platform's economics—capex, per-treatment consumable cost, and patient pricing tolerance—will determine whether it gains meaningful share against entrenched players like InMode and Cutera. Monitor Sofwave's installed base growth and average revenue per device as indicators of market acceptance.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.